{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T10:11:55Z","timestamp":1767867115437,"version":"3.49.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ymgmr.2022.100843","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T05:00:59Z","timestamp":1643691659000},"page":"100843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients"],"prefix":"10.1016","volume":"30","author":[{"given":"Richard W.D.","family":"Welford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herve","family":"Farine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Garzotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostantin","family":"Dobrenis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Sievers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmina","family":"Amraoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.A.","family":"Groenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Mengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2022.100843_bb0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cts.12500","article-title":"Future of rare diseases research 2017\u20132027: an IRDiRC perspective","volume":"11","author":"Austin","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0010","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: a critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0015","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1566523218666180404162622","article-title":"Genetics and therapies for GM2 gangliosidosis","volume":"18","author":"Cachon-Gonzalez","year":"2018","journal-title":"Curr. Gene. Ther."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ymgme.2008.04.012","article-title":"GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects","volume":"94","author":"Brunetti-Pierri","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176213","article-title":"GM2 gangliosidoses: clinical features, pathophysiological aspects, and current therapies","volume":"21","author":"Leal","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0035","doi-asserted-by":"crossref","first-page":"e1233","DOI":"10.1542\/peds.2011-0078","article-title":"Natural history of infantile G(M2) gangliosidosis","volume":"128","author":"Bley","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0040","doi-asserted-by":"crossref","first-page":"e1550","DOI":"10.1542\/peds.2006-0588","article-title":"The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported","volume":"118","author":"Maegawa","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ymgme.2017.12.432","article-title":"Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: volumetric quantitative MRI study","volume":"123","author":"Nestrasil","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0050","article-title":"Characterization of glycan substrates accumulating in GM1 gangliosidosis","volume":"21","author":"Lawrence","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jpeds.2019.08.016","article-title":"The clinical and molecular Spectrum of GM1 gangliosidosis","volume":"215","author":"Arash-Kaps","year":"2019","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0060","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/ajmg.a.37468","article-title":"MRI\/MRS as a surrogate marker for clinical progression in GM1 gangliosidosis","volume":"170","author":"Regier","year":"2016","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0065","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ymthe.2019.05.018","article-title":"Substrate reduction therapy for sandhoff disease through inhibition of glucosylceramide synthase activity","volume":"27","author":"Marshall","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0070","doi-asserted-by":"crossref","first-page":"13532","DOI":"10.1074\/jbc.RA119.009811","article-title":"Intracerebroventricular enzyme replacement therapy with beta-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice","volume":"295","author":"Chen","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0075","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41436-020-00968-z","article-title":"Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with fabry disease","volume":"23","author":"Bichet","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0080","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1042\/EBC20190090","article-title":"Lyso-glycosphingolipids: presence and consequences","volume":"64","author":"van Eijk","year":"2020","journal-title":"Essays Biochem."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197159","article-title":"Value of glucosylsphingosine (Lyso-Gb1) as a biomarker in gaucher disease: a systematic literature review","volume":"21","author":"Revel-Vilk","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002583","article-title":"Lysosomal re-acidification prevents lysosphingolipid-induced lysosomal impairment and cellular toxicity","volume":"14","author":"Folts","year":"2016","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0105","doi-asserted-by":"crossref","first-page":"20097","DOI":"10.1073\/pnas.1912108116","article-title":"Genetic ablation of acid ceramidase in krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target","volume":"116","author":"Li","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1515\/bchm3.1986.367.1.241","article-title":"Occurrence of lysoganglioside lyso-GM2 (II3-Neu5Ac-gangliotriaosylsphingosine) in GM2 gangliosidosis brain","volume":"367","author":"Neuenhofer","year":"1986","journal-title":"Biol. Chem. Hoppe Seyler"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0115","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1471-4159.1987.tb00969.x","article-title":"Composition of gangliosides and neutral glycosphingolipids of brain in classical tay-sachs and sandhoff disease: more lyso-GM2 in sandhoff disease?","volume":"49","author":"Rosengren","year":"1987","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029074","article-title":"Lyso-GM2 ganglioside: a possible biomarker of tay-sachs disease and sandhoff disease","volume":"6","author":"Kodama","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181700","article-title":"LC-MS\/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: a novel tool for the screening of sphingolipidoses and niemann-pick type C disease","volume":"12","author":"Pettazzoni","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0130","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1515\/cclm-2018-1301","article-title":"Plasma and dried blood spot lysosphingolipids for the diagnosis of different sphingolipidoses: a comparative study","volume":"57","author":"Polo","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0135","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/jimd.12269","article-title":"Detection of GM1-gangliosidosis in newborn dried blood spots by enzyme activity and biomarker assays using tandem mass spectrometry","volume":"44","author":"Su","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0140","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0145","first-page":"1324","article-title":"Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients","volume":"90","author":"Sejbaek","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0150","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","article-title":"Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Lu","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0155","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8110523","article-title":"Blood neurofilament light chain: the Neurologist's Troponin?","volume":"8","author":"Thebault","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0165","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/acn3.50942","article-title":"Neurofilament light is a treatment-responsive biomarker in CLN2 disease","volume":"6","author":"Ru","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155188","article-title":"Characterization of fluid biomarkers reveals lysosome dysfunction and neurodegeneration in neuronopathic MPS II patients","volume":"21","author":"Bhalla","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0175","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0180","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.neubiorev.2016.05.009","article-title":"Blood biomarkers for brain injury: what are we measuring?","volume":"68","author":"Kawata","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0185","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.brainres.2014.12.027","article-title":"Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease","volume":"1600","author":"Petzold","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0195","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00691417","article-title":"The white matter in G M2 gangliosidosis. A comparative histopathological and biochemical study","volume":"24","author":"Haberland","year":"1973","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s100240050010","article-title":"Infantile G(M1) gangliosidosis: complete morphology and histochemistry of two autopsy cases, with particular reference to delayed central nervous system myelination","volume":"3","author":"Folkerth","year":"2000","journal-title":"Pediatr. Dev. Pathol."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0205","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0887-8994(92)90361-2","article-title":"Dysmyelinogenesis in animal model of GM1 gangliosidosis","volume":"8","author":"Kaye","year":"1992","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0210","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11745-008-3268-0","article-title":"Comparative analysis of brain lipids in mice, cats, and humans with sandhoff disease","volume":"44","author":"Baek","year":"2009","journal-title":"Lipids"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0215","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002465R","article-title":"ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases","volume":"35","author":"Pouzol","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0220","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ymgme.2016.06.004","article-title":"Diagnostic tests for niemann-pick disease type C (NP-C): a critical review","volume":"118","author":"Vanier","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0225","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/TACG.S85354","article-title":"Animal models of GM2 gangliosidosis: utility and limitations","volume":"9","author":"Lawson","year":"2016","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0230","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng1095-170","article-title":"Mouse models of tay-sachs and sandhoff diseases differ in neurologic phenotype and ganglioside metabolism","volume":"11","author":"Sango","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021758","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of sandhoff disease","volume":"6","author":"Ashe","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0240","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ymgme.2017.04.011","article-title":"Infantile gangliosidoses: mapping a timeline of clinical changes","volume":"121","author":"Jarnes Utz","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0245","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/cts.12911","article-title":"Assessment of target engagement in a first-in-human trial with sinbaglustat, an iminosugar to treat lysosomal storage disorders","volume":"14","author":"Gehin","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072566","article-title":"Mechanism of secondary ganglioside and lipid accumulation in lysosomal disease","volume":"21","author":"Breiden","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0255","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ymgme.2020.07.006","article-title":"Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses","volume":"131","author":"Derrick-Roberts","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0260","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/0004867419893431","article-title":"Cerebrospinal fluid neurofilament light chain is elevated in niemann-pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response","volume":"54","author":"Eratne","year":"2020","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.ymgmr.2022.100843_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10204796","article-title":"Plasma neurofilament light (NfL) in patients affected by niemann-pick type C disease (NPCD)","volume":"10","author":"Dardis","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0270","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fnins.2020.00579","article-title":"Neurofilament-light chain as biomarker of neurodegenerative and rare diseases with high translational value","volume":"14","author":"Loeffler","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0275","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1523\/JNEUROSCI.4860-11.2012","article-title":"Lysosomal dysfunction in a mouse model of sandhoff disease leads to accumulation of ganglioside-bound amyloid-beta peptide","volume":"32","author":"Keilani","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0280","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ymgme.2014.11.015","article-title":"Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses","volume":"114","author":"Utz","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2022.100843_bb0285","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/hmg\/ddy012","article-title":"Intravenous administration of scAAV9-hexb normalizes lifespan and prevents pathology in sandhoff disease mice","volume":"27","author":"Niemir","year":"2018","journal-title":"Hum. Mol. Genet."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426922000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:52:14Z","timestamp":1762001534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426922000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":57,"alternative-id":["S2214426922000039"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100843","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100843"}}